Core Viewpoint - *ST Changyao's stock is at risk of being delisted due to continuous low trading prices and potential financial irregularities [1] Group 1: Stock Performance - As of January 14, 2026, *ST Changyao's stock closed at 0.78 yuan, down 1.27% from the previous trading day [1] - The stock opened at 0.79 yuan, reached a high of 0.82 yuan, and a low of 0.77 yuan, with a trading volume of 33.24 million yuan and a turnover rate of 11.98% [1] Group 2: Risk of Delisting - The company issued its seventh risk warning regarding the potential termination of its stock listing due to trading, financial issues, and significant legal violations [1] - The stock price has been below 1 yuan for ten consecutive trading days, and the market capitalization has been below 300 million yuan for four days [1] - The estimated net assets for the end of 2025 are expected to be negative, and the financial report may receive a non-standard opinion [1] - The company has received a preliminary notice of administrative punishment from the CSRC for false records in its annual reports from 2021 to 2023, which may lead to mandatory delisting [1] - A subsidiary of the company has also been declared bankrupt, and related risk warnings have been issued multiple times [1]

证券代码：300391 证券简称：*ST长药 公告编号：2026-005 长江医药控股股份有限公司 特别提示： 1、公司股票可能被实施交易类强制退市。2026年1月14日，长江医药控股 股份有限公司（以下简称"公司"或"长药控股"）股票收盘价格为0.78元/股， 已连续十个交易日均低于1元；公司股票收盘市值2.73亿元，已连续四个交易日 均低于3亿元。根据《深圳证券交易所创业板股票上市规则》第10.2.1条的规定， 若公司出现连续二十个交易日的股票收盘价均低于1元，或者连续二十个交易日 的股票收盘市值均低于3亿元，公司股票将被终止上市。根据《深圳证券交易所 创业板股票上市规则》第10.7.1条的规定，若公司股票因触及交易类强制退市 规定被实施交易类强制退市，公司股票不进入退市整理期。 2、公司股票可能被实施财务类强制退市。公司股票自2025年4月22日起被 实施退市风险警示和其他风险警示，自2025年12月29日起被叠加实施退市风险 警示。鉴于公司未在2025年12月31日前完成重整，2025年度期末净资产预计为 负（具体准确的财务数据以公司正式披露经审计后的2025年年度报告为准）。 如公司2025年度期末 ...

Group 1 - The stock price of *ST Changyao (300391) closed at 0.79 yuan on January 13, 2026, down 2.47%, with a turnover rate of 16.39% and a trading volume of 574,300 shares, amounting to a transaction value of 45.203 million yuan [1] - The company is at risk of being delisted due to trading, financial issues, and significant legal violations, as its stock price has been below 1 yuan for nine consecutive trading days and its market capitalization has been below 300 million yuan for three days [1][2] - The company anticipates a negative net asset for the fiscal year 2025, and its financial report may receive a non-standard opinion, indicating serious financial distress [1] - The company has received a notice of administrative penalty from the China Securities Regulatory Commission (CSRC) due to false records in its annual reports from 2021 to 2023, which may lead to mandatory delisting [1] - A subsidiary of the company has been declared bankrupt, and a manager has been appointed [1] Group 2 - On January 13, 2026, there was a net outflow of 2.839 million yuan from main funds, indicating continued withdrawal by major investors [2] - The stock has been trading below 1 yuan for nine consecutive days, highlighting the risk of delisting due to trading-related issues [2]

Core Viewpoint - *ST Changyao's stock is at risk of being delisted due to continuous low trading prices and potential financial irregularities [1] Group 1: Stock Performance - As of January 13, 2026, *ST Changyao's stock closed at 0.79 yuan, down 2.47% from the previous trading day [1] - The stock opened at 0.80 yuan, reached a high of 0.83 yuan, and a low of 0.76 yuan, with a trading volume of 45.203 million yuan and a turnover rate of 16.39% [1] Group 2: Risk of Delisting - The company issued a risk warning regarding the potential termination of its stock listing due to trading, financial issues, and significant legal violations [1] - The stock price has been below 1 yuan for nine consecutive trading days, and the market capitalization has been below 300 million yuan for three days [1] - The projected net assets for 2025 are expected to be negative, and the financial report may receive a non-standard opinion [1] - The company has received a preliminary notice of administrative punishment from the CSRC for false records in annual reports from 2021 to 2023, which may lead to mandatory delisting due to significant legal violations [1] - A subsidiary of the company has been declared bankrupt, and a manager has been appointed [1]

Core Viewpoint - *ST长药 is facing potential delisting due to its stock price and market capitalization falling below regulatory thresholds, with significant financial distress indicated by negative net assets expected for the fiscal year 2025 [1] Group 1: Stock Performance - As of January 13, 2026, the company's stock closed at 0.79 yuan per share, remaining below 1 yuan for nine consecutive trading days [1] - The company's market capitalization is reported at 2.77 billion yuan, having been below 3 billion yuan for three consecutive trading days [1] Group 2: Regulatory Compliance - According to the Shenzhen Stock Exchange's rules, if the stock price remains below 1 yuan or the market capitalization below 3 billion yuan for twenty consecutive trading days, the stock will be delisted [1] - The company has been under delisting risk warnings since April 22, 2025, and has faced additional warnings since December 29, 2025 [1] Group 3: Financial Condition - The company is expected to report negative net assets for the fiscal year ending December 31, 2025, pending the final audited financial report [1] - If the audited net assets are negative or if the financial report receives a qualified, adverse, or disclaimer opinion, the company will trigger mandatory delisting conditions [1]

Core Viewpoint - Company *ST Changyao (300391.SZ) is at risk of being delisted due to its stock price and market capitalization falling below regulatory thresholds [1] Group 1: Stock Performance - As of January 13, 2026, the company's stock closed at 0.79 yuan per share, having been below 1 yuan for nine consecutive trading days [1] - The company's market capitalization is 277 million yuan, which has been below 300 million yuan for three consecutive trading days [1] Group 2: Regulatory Compliance - According to the Shenzhen Stock Exchange's GEM Listing Rules, if the company's stock price remains below 1 yuan for twenty consecutive trading days, or if its market capitalization stays below 300 million yuan for the same period, it will face delisting [1] - The company has been under delisting risk warnings since April 22, 2025, and has faced additional warnings since December 29, 2025 [1] Group 3: Financial Status - The company is expected to report a negative net asset value at the end of 2025, pending the official audited annual report [1] - If the audited net assets for 2025 are negative, or if the financial report receives a qualified opinion, disclaimer, or adverse opinion, the company will trigger mandatory delisting conditions [1]

2、公司股票可能被实施财务类强制退市。公司股票自2025年4月22日起被 实施退市风险警示和其他风险警示，自2025年12月29日起被叠加实施退市风险 警示。鉴于公司未在2025年12月31日前完成重整，2025年度期末净资产预计为 负（具体准确的财务数据以公司正式披露经审计后的2025年年度报告为准）。 如公司2025年度期末经审计净资产为负值，或者2025年度财务会计报告被出具 保留意见、无法表示意见或者否定意见的审计报告，根据《深圳证券交易所创 业板股票上市规则》第10.3.11条的规定，公司触及财务类强制退市情形，公司 股票将被终止上市。敬请广大投资者注意投资风险。 截至本公告披露日，公司可能触及的终止上市情形如下： 具体情形 是否适用 （对可能触及的打勾） 1 证券代码：300391 证券简称：*ST长药 公告编号：2026-004 长江医药控股股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、公司股票可能被实施交易类强制退市。2026年1月13日，长江医药控股 股份有限公司（以下简 ...

Group 1 - The average stock price of A-shares is 14.69 yuan, with 31 stocks priced below 2 yuan, the lowest being *ST Changyao at 0.79 yuan [1] - Among the low-priced stocks, 9 are ST stocks, accounting for 29.03% of the total [1] - The Shanghai Composite Index closed at 4138.76 points as of January 13 [1] Group 2 - Among the low-priced stocks, 12 increased in price today, with Dongtong Tui rising by 3.80%, Kangmei Pharmaceutical by 1.54%, and Jieneng Tiexin by 1.07% [1] - 15 low-priced stocks decreased, with Rongsheng Development falling by 6.59%, *ST Aowei by 5.22%, and *ST Lifang by 3.96% [1] - The stock price performance of low-priced stocks shows a mixed trend, indicating volatility in this segment [1][2]

Core Viewpoint - Long Pharmaceutical Holdings (300391) is facing significant legal and financial challenges due to false financial reporting and potential forced delisting from the Shenzhen Stock Exchange, which has led to investor claims for compensation [2][4]. Group 1: Legal Issues - The Wuhan Intermediate People's Court has accepted batch claims from investors against Long Pharmaceutical Holdings, with ongoing efforts to accept more claims [1][3]. - There have been precedents of successful claims by investors against Long Pharmaceutical Holdings, indicating a potential for further compensation opportunities [1][3]. Group 2: Financial Misreporting - The company has been found to have inflated its revenue and profit figures in its annual reports for 2021, 2022, and 2023, with inflated revenues of 215.32 million, 283.74 million, and 233.63 million respectively, representing 9.12%, 17.57%, and 19.51% of reported revenues [2][4]. - The inflated profit totals were 56.40 million, 63.38 million, and 43.71 million for the same years, accounting for 35.62%, 88.23%, and 6.42% of reported profits [2][4]. - The company may face forced delisting due to continuous false reporting of financial metrics over three years, as per the Shenzhen Stock Exchange regulations [2][4]. Group 3: Financial Health - As of the latest report, Long Pharmaceutical Holdings has a significant fund occupation amounting to 179.66 million, which is 92.08% of its latest audited net assets [3][5]. - The company plans to resolve the fund occupation through the transfer of debts with related parties [3][5].

Group 1 - Small-cap stocks exhibit higher volatility and activity compared to large-cap stocks, making them more likely to become market leaders [1] - As of January 12, there are 847 stocks with a circulating market value below 3 billion yuan, and 326 of these have a circulating market value below 2 billion yuan [1] - A total of 1,498 stocks have a total market value below 5 billion yuan, with 482 stocks having a total market value below 3 billion yuan [1] Group 2 - The three stocks with the smallest circulating market values are *ST Changyao at 284 million yuan, *ST Aowei at 354 million yuan, and Kuntai Co. at 636 million yuan [1] - The three stocks with the smallest total market values are *ST Changyao at 284 million yuan, *ST Aowei at 399 million yuan, and *ST Lifang at 648 million yuan [1] - A detailed list of stocks with circulating market values below 2 billion yuan includes various sectors such as pharmaceuticals, defense, automotive, and more, highlighting the diversity within small-cap stocks [1][2]